The immuno-oncology drug developer, spun out of Johannes Gutenberg University Mainz, has filed for a $100m offering in the US.
Biontech, a Germany-based cancer immunotherapy developer spun out of Johannes Gutenberg University Mainz, has filed for a $100m initial public offering on the Nasdaq Global Select Market.
The filing comes after reports in March this year that the company would target $800m in a forthcoming IPO but it is yet to set a price range.
Biontech is working on the development of individualised immunotherapies to treat cancer and potentially other diseases.
Part of the IPO proceeds…